Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial

Authors

• Susan B Bressler, Johns Hopkins University
• Rajendra S Apte, Washington University School of Medicine in St. Louis
• et al.

Journal

JAMA Ophthalmology

Publication Date

10-1-2024

Volume

142

Issue

10

First Page

952

Last Page

960

Document Type

Open Access Publication

DOI

10.1001/jamaophthalmol.2024.3458

Rights and Permissions

Bressler SB, Barve A, Ganapathi PC, et al. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial. JAMA Ophthalmol. 2024;142(10):952–960. doi:10.1001/jamaophthalmol.2024.3458. This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2024 Bressler SB et al. JAMA Ophthalmology.

Recommended Citation

Bressler, Susan B; Apte, Rajendra S; and et al., "Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial." JAMA Ophthalmology. 142, 10. 952 - 960. (2024).
https://digitalcommons.wustl.edu/oa_4/7676

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.